EXC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exelon Corp (EXC) is not a strong buy for a beginner, long-term investor at this moment. While the company has positive developments such as hedge fund buying and approval for a significant transmission line project, its recent financial performance shows declining revenue, net income, and EPS. Analysts have mixed views, with some citing regulatory uncertainties and affordability challenges. The technical indicators suggest a neutral to slightly bullish trend, but there are no strong proprietary trading signals or congress trading data to support an immediate buy decision. Holding or waiting for a better entry point may be more prudent.
The technical indicators for EXC are moderately bullish. The MACD is positive and contracting, RSI is neutral at 65.472, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 46.224, R1: 48.348, S1: 44.1, R2: 49.66, S2: 42.788. However, the stock's next-month trend prediction shows a potential decline of -7.88%, which warrants caution.
Approval of a 765 kV transmission line project with NextEra Energy, aimed at improving reliability and affordability.
Hedge funds are significantly increasing their holdings, with a 2344.75% increase in buying over the last quarter.
Analysts have raised price targets recently, with some maintaining Outperform ratings.
Declining financial performance in Q4 2025, with revenue, net income, and EPS all showing YoY decreases.
Regulatory and political uncertainties in key states, as highlighted by analysts.
Wolfe Research downgraded the stock, citing below-average earnings growth and valuation concerns.
In Q4 2025, Exelon reported a revenue drop of -1.08% YoY to $5.41 billion. Net income declined by -8.19% YoY to $594 million, and EPS fell by -7.81% YoY to $0.59. However, gross margin improved by 11.50% YoY to 54.19%.
Analysts have mixed views on EXC. Recent upgrades include price target increases to $51 by BMO Capital and Mizuho, citing positive Q4 results and growth prospects. However, Wolfe Research downgraded the stock, citing regulatory noise and below-average earnings growth. Scotiabank remains cautious due to affordability challenges and regulatory uncertainty.
